Tipperenx
Billionaire Ken Griffin leads these 3 “Strong Buy” stocks
As the tech bubble and fears of a stretched valuation become the talk of the town, investors have turned to the Wall Street Titans for guidance, namely Ken Griffin. Founded in 1990 by hedge fund Citadel, the company now has હેઠળ 35 billion in assets under management. As a 19-year-old sophomore at Harvard University, Griffin started trading with fax machines, computers and phones from his dorm room. Now, the CEO of Citadel, whose total wealth is .5 15.5 billion, is considered the greatest of Wall Street. Judging by the performance of the fund during the Covid crisis, it is even clearer why Griffin has the legendary status. Like the average hedge fund, which had a negative return of 3-4-3% in the first half of 2020, Citadel’s flagship Wellington Fund returns between 13 and 14% for the same period it saw. With this in mind, we want to take a closer look at the three stocks Citadel recently called. Using TipRanx’s database, we found that each ticker received a “Strong Buy” consensus rating from the analyst community. Not to mention those three people have a lot of potential business potential. AVEO Pharmaceuticals (AVEO) In the hope of providing better results for patients, AEO Pharmaceuticals promotes drugs targeted for oncology and other unmet medical requirements. Given an important regulatory goal, it is no surprise that all eyes are on the name of this healthcare. Griffin is one of the people who praised AVEO. Citadel bought 383,720 shares in Q2, increasing its holding by a total holding.35 2.7%. The total position is now 8,824,013 with 100,00003 shares falling. HC Winewright analyst Swayampakula Ramakant reminded investors that on June 1 the FDA accepted TVNib, NDA for review, based on the fact that the TIVO-3 study has a positive final overall survival (OS) data report. In the study, A.E.E.O. The treatment was compared with sorfenib, marketed as a nexavar by Bayer for the treatment of advanced renal cell carcinoma (RCC) in third- and fourth-line settings. At the 2020 Virtual Meeting, the final OS analysis resulted in an overall Crisis Ratio (HR) of 0.97, which favored Tivoznib. Ramakant was “encouraged” by the Om results because he suggested that Tivoznib had at least the same risk of death as Sorophenib. ”The primary endpoint of both Progress Free Existence (PFS) was found in view of the TIVO-3 study. The secondary final point of the overall response rate (ORR) with the active comparable OS, we believe that Tivoznib will get the green light for US approval, which could be a major catalyst in the next 12 months, “Ramakant added. Dosage escalation for B / 2 low studies, evaluation of tivoznib in combination with Durvalumb, a monoclonal antibody against PD-L1, has been marketed as an infusion by Astrazeneca in hepatocellular carcinoma (HCC). With approximately 33,000 patients suffering from liver cancer each year in India, Ramkanth sees an additional opportunity. For this, Ramkanth rates the Avio by rating with a price target of AV 12. If his thesis runs, 163% in the card. Twelve months could be a potential benefit. (To see Ramkanth’s track record, click here) Other analysts do not request to be different. 3 Buy ratings in the last three months and no holdings or sales assigned. So, the word on the street is that AVEO is a Strong buying is averaging 15 15 The price target is more aggressive than Ramkanth and suggests a 229% side lattice potential. (See AVEO Stock Analysis on Tipranx) Next to Idea Biosciences (IDYA) we have Idea Biosciences, an oncology-focused precision medicine company that develops targeted therapies using molecular diagnostics. Based on the power of its technique, many fans have registered with this name. Choosing a new position for Griffin’s Citadel, the fund pulls on 248,005 shares of Q2. If we talk about the value of this holding, it comes to 2,881,818. Writing for Northland Capital, analyst Tim Chiang believes the stock “is evaluated based on the future potential of its precision drug oncology pipeline, targeting specific biomarkers.” Elaborating on this, he said, “Idea is using its capabilities in many categories of precision drugs, including the direct targeting of anchogenic pathways and synthetic lethality – representing an emerging class of precision drug targets. , According to Chiang, is the fact that its antecedent applications use its synthetic lethality (SL) platform, which targets tumors with homologous recombination deficiency (HRD), including MTAP gene deletion and BRC mutation. “We believe that the long-term side effect with IDYA is significant. The share is significant considering the potential usefulness of SL. The first clinically validated SL gene pair was PEP-BRCA 1/2, and based on the effectiveness of PARP inhibitors, SL approaches to cancer treatment have significantly expanded. Behind this, Chiang points out that many PARP inhibitors have already been approved for the treatment of tumors, including ovarian, breast, and pancreatic cancer, in the form of BRCA and other DNA damage repair modifications. These inhibitors include Astrazenecinac laparib. “We estimate that the four drugs will generate more than 6 1.6 billion in global sales in 2019 and that sales are expected to exceed 6 6 billion by 2024,” he said. It should be noted that multiple IND filings are set to come within the next 4-12 months, with IDYA’s main SL candidate, IDE397, which was created to prevent MTAP and MAT2A, and thus the number of cancerous tumor cells entering the clinic in 2021. Not surprisingly, after that, Chiang joined the bulls.To start his IDY coverage, he puts an outperforming rating on the stock and a price target of લ 28. This target indicates a potential twelve-month growth horizon. (To view Chiang’s track record, click here) Similarly, the rest of the street is being found onboard. Buy the ratings assigned in the last three months, add to the Strong by Analyst Consensus. In addition, the average price target of 25.20 is the potential bar. -Occular Therapeutics (OCUL) using its patented birosorbable hydrogel-based formulation technique, Ocular Therapeutics for diseases and eye conditions. Comes. The progress of its clinical programs has caught the attention of Wall Street, with some arguing that now is the time to take action. Griffin and Citadel didn’t want to miss a chance. Hedge funds have increased their holdings by 272%, breaking 161,032 shares during Q2. The total position now stands at 220,269 shares and is valued at 1,718,098 dollars. Raymond James ’broadcast, 5-star analyst Dan Leo has shown the potential to address the urgent need for dry eye disease indication as a key component of his bullish thesis. Given this situation, the company has two assets, OTX-CSI (chronic) and OTX-DED (acute). OTX-CSI has incorporated the FDA-approved immunomodulator cyclosporine as an active drug into intracranial nucleus insert, released for approximately three months to increase tear production. When it comes to OTX-DED, Leo argued that OCUL was “smart enough to drive growth. OTX-DED (a low-dose form of dextranza, a corticosteroid intraocular nerve inserted into the peritoneum, a natural opening in the eye’s idiom, and dezamethasone to deliver up to 30 days without preservatives to the pre-cooler surface) 2-Enables management to enable. “Speaking of the potential opportunity here, both products” can generate revenue for physicians in the treatment of dryness. In Leon’s opinion, C.P.T. Eyes using Code 0356T, which currently provides incentives for rapid adoption in the dry eye space valued at .5.1 billion. The ND Regulatory Path for Clinical A, Phase 2 for OTX-DED will begin in Trial 2H21, shortly after OTX-CSI, which will see Phase 2 clinical trials evaluating two different formulations initiated by 4Q20. Based on the short treatment duration of OTX-DED, management thinks it will still be brought to market first. For this, Leon is optimistic about the company’s long-term growth statement. As a result, OCUL rates a strong buy, with a price target of C15. This figure indicates that the stock may rise 89% in the coming year. (To see Leon’s track record, click here) Turning to the rest of the street, the other analysts are on the same page. With 100% street support, or 3 bye ratings being accurate, the consensus is unanimous: OCUL is a strong buy. . The average price target of 13.50 brings 70% of the potential to the side. (See OQL Stock Analysis on Tipranx) To find good ideas for trading stocks at attractive valuations, visit Tipranx’s Best Stock to Buy, which unites all of Tipranx’s equity insights. Disclaimer: The views expressed in this article are those of the specific analysts. Content is intended for informational purposes only. It is very important to do your own analysis before making any investment.
